Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer

Author:

Oh Do-Youn1,Ruth He Aiwu2,Qin Shukui3,Chen Li-Tzong456,Okusaka Takuji7,Vogel Arndt8,Kim Jin Won9,Suksombooncharoen Thatthan10,Ah Lee Myung11,Kitano Masayuki12,Burris Howard13,Bouattour Mohamed14,Tanasanvimon Suebpong15,McNamara Mairéad G.16,Zaucha Renata17,Avallone Antonio18,Tan Benjamin19,Cundom Juan20,Lee Choong-kun21,Takahashi Hidenori22,Ikeda Masafumi23,Chen Jen-Shi24,Wang Julie25,Makowsky Mallory25,Rokutanda Nana25,He Philip25,Kurland John F.25,Cohen Gordon25,Valle Juan W.16

Affiliation:

1. Division of Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea

2. Division of Hematology and Oncology, Georgetown Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC

3. Cancer Center of Nanjing, Jinling Hospital, Nanjing, China

4. Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan

5. National Institute of Cancer Research, Tainan, Taiwan

6. National Cheng Kung University Hospital, National Cheng Kung University, Tainan, Taiwan

7. Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan

8. Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany

9. Division of Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea

10. Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand

11. Division of Medical Oncology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University, Seoul, South Korea

12. Second Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan

13. Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN

14. Department of Liver Cancer Unit, Assistance Publique–Hôpitaux de Paris Hôpital Beaujon, Paris, France

15. Department of Internal Medicine, Faculty of Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital, Bangkok, Thailand

16. Division of Cancer Sciences, The University of Manchester/The Christie NHS Foundation Trust, Manchester, UK

17. Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk, Poland

18. Istituto Nazionale Tumori-IRCCS Fondazione G. Pascale, Naples, Italy

19. Department of Medicine, Washington University School of Medicine, St. Louis, MO

20. Instituto de Investigaciones Metabólicas, Buenos Aires, Argentina

21. Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea

22. Department of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan

23. Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan

24. Department of Hematology-Oncology, Linkou Chang-Gung Memorial Hospital and Chang-Gung University, Taoyuan City, Taiwan

25. AstraZeneca, Gaithersburg, MD

Publisher

Massachusetts Medical Society

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3